Table 7.

Effects of vildagliptin on insulin sensitivity (level 2 evidence)

Design	Treatment and dose	Outcome		Reference
		Oral glucose insulin sensitivity (mL/min/m2)	Adaptation index (insulin secretion x insulin sensitivity)
					Double-blind, placebo-controlled, multicenter RCT, 12 weeks Optional extension for further 40 weeks	Placebo (n=51, of whom 29 completed extension) V 50 mg qd (n=56, of whom 42 completed extension All patients were also taking stable doses of metformin 1.5–3 g/day	Greater with V than placebo at 24 and 52 weeks (P<0.05)	Greater with V than placebo at 12, 24 (P<0.05), and 52 weeks (P<0.01)	Ahrén et al. 2005b

qd, once daily; RCT, randomized controlled trial; V, vildagliptin.